close
Home
#WE-WONT-REST
chevron_right
News & Events
chevron_right
About medicines
chevron_right
More Than Medicine
chevron_right
Pharmaceutical Legislation
Relationships & code
chevron_right
Publications
chevron_right
About us
chevron_right
Contact us
KMS Login
arrow_back
close
#WE-WONT-REST
Patient stories
expand_more
expand_less
chevron_right
Alzheimer's patient story
Blood cancer patient story
Lung cancer patient story
Haemophilia patient story
Members updates
Imagine
News & Events
The EFPIA View
Events
Newsletter
About medicines
Development of medicines
expand_more
expand_less
chevron_right
Animal Use and Welfare
Antimicrobial resistance (AMR)
Digital Health
Intellectual Property
Precision medicine
Public-private partnerships
Regulations, safety & supply
SMEs in Europe
Trade
Unmet medical need
Use of medicines
expand_more
expand_less
chevron_right
HTA & Relative Efficacy Assessment
Disease-specific groups
Healthcare Systems
Value of medicines
Access to medicines
expand_more
expand_less
chevron_right
Back Innovation, Boost Access
More Than Medicine
Improving Health
Turning science into new medicines
Responsible Innovation
Economic impact
Pharmaceutical Legislation
Relationships & code
The EFPIA Code
Patient organisations
Healthcare professionals (HCPs)
Disclosure of payments
National codes
EU institutions
Publications
Data center
Downloads
Cancer Comparator Report
expand_more
expand_less
chevron_right
About
Recommendations
Cancer Cases
Cancer Deaths
Survival
Cancer Care
Cancer Types
Resources
About us
Who we are
EFPIA Japan
Membership
Job vacancies
Partnerships & Initiatives
Contact us
arrow_back
close
Development of medicines
Animal Use and Welfare
Antimicrobial resistance (AMR)
Digital Health
Intellectual Property
Precision medicine
Public-private partnerships
Regulations, safety & supply
SMEs in Europe
Trade
Unmet medical need
Use of medicines
HTA & Relative Efficacy Assessment
Disease-specific groups
Healthcare Systems
Value of medicines
Access to medicines
Back Innovation, Boost Access
Cancer Comparator Report
About
Recommendations
Cancer Cases
Cancer Deaths
Survival
Cancer Care
Cancer Types
Resources
News & Events
The EFPIA view
#WeWontRest until...
#WeWontRest until we make treatments for rare disease less rare
close
#WeWontRest until we make treatments for rare disease less rare
Some diseases are rare. Treating them shouldn't be.
apps
The EFPIA View
chevron_left
Previous
print
Print
Next
chevron_right
#WeWontRest until we make treatments for rare disease less rare
24.02.21
How has the Orphan Regulation contributed to addressing unmet medical needs for rare disease?
Is it time for a revision of the OMP Regulation?
What can be done to support faster more equitable access to orphan medicines to patients?
How can our regulatory system help new medicines get to patients faster?
What are the development challenges specific to orphan medicines?
How are R&D decisions taken?
40% of new medicines in the pipeline are orphan medicines. What does the future hold?
close
continue